Mittwoch, 30. August 2023

NEWS - Medicine Without Blood (Second) / Should Anyone Be Given a Blood Transfusion? (2015)

SHOULD ANYONE BE GIVEN A BLOOD TRANSFUSION?



By Amanda Schaffer

August 13, 2015



This is the second part in a three-part series, “Medicine Without Blood,” about the ways that Jehovah’s Witnesses have changed the way that doctors think about blood transfusion. Read the first and third installments, “How Jehovah’s Witnesses Are Changing Medicine” and “The Ethics of Bloodless Medicine.”


The United States’ full embrace of blood transfusion began during the Second World War, when large-scale blood donation and mobilization became part of the war effort. “Your blood, as a gift, is unlike money, unlike time or work,” one radio broadcast, titled “Women at War,” announced. It was a gift “to an American soldier or sailor, who may live to save all that you count precious in the world.” One Marine Corps correspondent described the arrival of blood at a medical station in the Pacific: “the wine-colored bottles were held aloft above the prone bodies [of wounded men] and the stuff was doing its miraculous work.” It was the “most precious cargo on this island of agony.” Japanese troops had nowhere near the same access to blood, which only heightened its symbolic power. The Germans, too, were hampered by a refusal to collect from non-Aryans, a policy that “eventually frustrated even their own physicians,” according to the journalist Douglas Starr, whose book “Blood: An Epic History of Medicine and Commerce” details this history.


After the war, donated blood became an integral part of Western medicine. Advances in care, including open-heart surgery, artificial kidney replacements, and trauma work “consumed huge amounts of blood,” Starr writes. Doctors also transfused patients to top off their hemoglobin levels following procedures like tonsillectomies, appendectomies, and even childbirth. Yet, in the thrall of wartime transfusion, blood had never been treated like an experimental drug and subjected to rigorous, randomized clinical trials assessing risk and benefit. Its power was intuitive. Doctors observed that patients with anemia seemed to feel better following transfusion. “The patients looked rosy and felt full of energy,” one older doctor told me. No one was thinking yet about adverse effects.


This made it difficult for Jehovah’s Witnesses who developed anemia or needed major surgery. The religion’s governing body had decided that passages in the Bible, which instruct adherents not to consume blood, meant that they should avoid transfusion. The mixing of blood seemed to them a form of existential contamination. Yet most Witnesses still wished to receive medical care. And “in some doctors’ minds, there was confusion,” Zenon Bodnaruk, of Hospital Information Services at the Jehovah’s Witnesses’ world headquarters, in Brooklyn, told me. Some doctors believed that the religious objection to blood transfusion was tantamount to a refusal of care. One frequent scenario involved patients with heart disease who needed coronary-artery bypass grafts or cardiac-valve-replacement surgeries, both of which involved substantial blood loss and were nearly always accompanied by transfusion. Jehovah’s Witnesses were repeatedly turned away by cardiac surgeons or “asked to reconsider their religious position on blood,” Bodnaruk said.


Still, a small number of doctors were willing to accommodate requests for bloodless treatment. In the late nineteen-seventies, Watch Tower leaders decided to cultivate relationships with these physicians. In the late eighties, the governing body approved a large-scale effort to help Witnesses find sympathetic care, according to Bodnaruk. In the early nineties, one of the institutions that Witnesses contacted was Englewood Hospital and Medical Center, in New Jersey, which welcomed them. Aryeh Shander, a voluble, grandfatherly man who was then the chief of anesthesiology at Englewood, became an important advocate for their cause. His empathy for religious minorities was strong, he said, because his mother was a Holocaust survivor and had impressed on him the importance of “always looking out for human rights.” At the same time, he had developed an academic interest in blood transfusion, which he believed, based mainly on intuition, was overused in surgery. There wasn’t any real evidence yet to prove him right or wrong.


From the beginning, the bloodless program at Englewood enjoyed anecdotal success. In small observational studies, the witnesses’ surgical outcomes seemed to match those of other patients undergoing the same procedures. By the late nineteen-nineties, Shander and his team were committed to applying the lessons of bloodless medicine to non-Witness patients. Englewood was not alone in this experience. Numerous bloodless-medicine programs had sprung up around the same time in the United States, thanks to the Jehovah’s Witnesses’ advocacy.


Meanwhile, the prevailing attitudes toward blood had grown more fraught, in the U.S. and elsewhere. Since the late nineteen-sixties, when patients with hemophilia began to use clot-promoting proteins that were derived from large pools of donor blood, they had been vulnerable to infection, especially hepatitis. In the early eighties, however, with the emergence of AIDS, risks soared. Before the development of an H.I.V. screening test for donors, in 1985, almost half of all hemophiliacs became infected with the virus.


Lawrence Tim Goodnough, who is now the director of the transfusion service at Stanford Medical Center, was a fellow in hematology oncology just as the H.I.V. epidemic began. His experience with hemophiliacs, in particular, inspired in him a lifelong interest in reducing patients’ exposure to blood. “I was not coming primarily from a Jehovah’s Witness point of view,” he said. But as bloodless-medicine programs developed, in the late nineteen-eighties and nineties, he found that the clinicians running them made natural bedfellows. Their experience was “key to showing how often you can get patients through complex hospitalizations, surgical and medical, without blood transfusions.”


In 1999, the first strong evidence to validate this perspective emerged. In arandomized controlled trial published in the New England Journal of Medicine, Canadian researchers found that more restrictive blood-transfusion practices could often be just as good for patients—or better. Interestingly, the lead researcher, a critical-care specialist named Paul Hébert, had expected to demonstrate just the opposite. He and his colleagues enrolled more than eight hundred critically ill patients in intensive-care units. These patients were not actively losing blood, but they suffered from anemia, a problem in which the blood lacks sufficient hemoglobin and struggles to transport oxygen through the body. Hébert and his team randomly assigned them to receive red-blood-cell transfusions either on a liberal or restrictive basis. After thirty days, the two groups had equivalent mortality. Among patients who were younger than fifty-five or who had less severe conditions, the probability of death was actually lower for those treated under the more restrictive guidelines.


At first, Hébert said he did not believe the results. But over the years, his work has been recognized as “one of the landmark papers in transfusion medicine,” according to Courtney Hopkins, the Chief Medical Officer of the American Red Cross’s eastern division. Numerous other randomized controlled trials have confirmed his core finding, as well. Researchers have compared restrictive and liberal transfusion strategies in critically ill children. They’ve also studied adults with septic shock, gastrointestinal bleeding, and traumatic brain injury, and those undergoing high-risk hip surgery. These papers have either found no difference between the two groups or have found better outcomes in those receiving less blood. (One exception has been patients with acute coronary events, such as heart attacks, for whom the evidence is mixed and may support more liberal transfusion, Hébert said.) Most physicians conducting this research have not worked in programs for Jehovah’s Witnesses. But the Witness community has taken note. So too have leaders of bloodless-medicine programs, many of whom are passionate advocates for reducing transfusion whenever possible. (The Society for the Advancement of Blood Management, the first national organization dedicated to this goal—founded by Shander, Goodnough, and others—has played a key role in disseminating best practices regarding patients’ blood.)


Hospital administrators have also zeroed in on the emerging evidence, because it allows them to cut costs associated with transfusion. “Maybe it was the great recession or maybe the winds of health reform,” Goodnough said, but since around 2009, an increasing number of hospitals have established programs dedicated to using blood more conservatively. From 2008 to 2011, the last year for which national data are available, transfusion in the U.S. decreased by more than eleven per cent—and, according to the American Red Cross, that trend has continued. Even blood bankers have joined the chorus; their major professional organization in the U.S, the American Association of Blood Banks, now sponsors workshops that teach techniques like boosting red blood cells before surgery, avoiding unnecessary blood draws and recycling blood cells to patients during procedures. “I’m teaching providers to use less of the product we sell,” Dr. Hopkins of the Red Cross said, “but that’s because we want to do what’s best for patients.”


From a medical standpoint, restricting transfusion may be helpful for a range of reasons. When red blood cells are stored, they become more rigid and undergo chemical changes that make them less efficient at carrying oxygen. (And, when doctors know that they won’t be able to transfuse, they may work harder to build up blood-cell counts and avoid squandering cells.) The extent to which transfusion may cause further, low-grade risks is hard to assess, since subtle harms—as well as subtle gains—can easily go unrecognized in patients who are already critically ill. For reasons that are not entirely clear, donor blood can suppress recipients’ immune systems, or it can trigger overactive immune responses, thanks to the waste products the cells secrete. A bag of blood that’s been sitting in storage is “like a dirty fish tank you haven’t cleaned in a month,” Patricia Ford, a hematologist at Pennsylvania Hospital, told me. And of course, while the risk of H.I.V. infection is now extremely low in the developed world, proponents worry about new pathogens.


This isn’t to say that transfusion is useless—just that it’s not nearly as useful as people used to believe. “I firmly believe that transfusions save lives,” Hébert said. “I transfuse in my practice all the time, just a little less than I used to.”


QUELLE: https://www.newyorker.com/news/news-desk/should-anyone-be-given-a-blood-transfusion






HISTORY - Blut als Heilmittel in der Antike

Römer tranken Gladiatorenblut als Heilmittel gegen Epilepsie!   Die alten Römer waren bekannt dafür, gewalttätige Formen der Unterhaltung zu...